Thaunat, Olivier <br/><br/>
B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.  [electronic resource] 

 -  Transplantation  Jun 2008 
 - 1648-53 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0041-1337 
<br/><br/><label>Standard No.: </label>10.1097/TP.0b013e3181735723  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD20<br/>B-Cell Activating Factor--biosynthesis<br/>B-Lymphocytes--drug effects<br/>Biopsy<br/>Cell Survival--drug effects<br/>Chronic Disease<br/>Female<br/>Flow Cytometry<br/>Follow-Up Studies<br/>Gene Expression<br/>Graft Rejection--drug therapy<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Isoantibodies--immunology<br/>Kidney Transplantation--immunology<br/>Male<br/>Prospective Studies<br/>RNA--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Rituximab<br/>Transplantation, Homologous<br/>Treatment Outcome